Section Arrow
VCNX.NASDAQ
- Vaccinex
(Financial Status)
Quotes are at least 15-min delayed:2024/10/31 19:24 EDT
Last
 2.79
-1.24 (-30.77%)
Day High 
4.81 
Prev. Close
4.03 
1-M High
4.1819 
Volume 
450.80K 
Bid
2.8
Ask
2.85
Day Low
2.76 
Open
4.01 
1-M Low
1.39 
Market Cap 
10.48M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.16 
20-SMA 2.7 
50-SMA 4.02 
52-W High 13.44 
52-W Low 1.39 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.96/-0.40
Enterprise Value
10.50M
Balance Sheet
Book Value Per Share
-1.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
570.00K
Operating Revenue Per Share
0.25
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.